SEC Company Response from Inari Medical, Inc. (NARI) (CIK 0001531048) — May 18, 2020
Inari Medical, Inc. (NARI) (CIK 0001531048)
Date: May 18, 2020 · CIK: 0001531048 · Accession: 0001193125-20-144409
AI Filing Summary & Sentiment
File numbers found in text: 333-236568
Letter
SEC Response Letter
650 Town Center Drive, 20th Floor
Costa Mesa, California 92626-1925
Tel: +1.714.540.1235 Fax: +1.714.755.8290
www.lw.com
FIRM / AFFILIATE OFFICES
May 18, 2020
Beijing
Boston
Brussels
Century City
Chicago
Dubai
Düsseldorf
Frankfurt
Hamburg
Hong Kong
Houston
London
Los Angeles
Madrid
Milan
Moscow Munich
New York
Orange County
Paris
Riyadh
San Diego
San Francisco
Seoul
Shanghai
Silicon Valley
Singapore
Tokyo
Washington, D.C.
VIA EDGAR AND OVERNIGHT DELIVERY
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention: Chris Edwards; Irene Paik; Jeanne Bennett; Kevin Kuhar
Re: Inari Medical, Inc.
Amendment No. 1 to Registration Statement on Form S-1
Filed May 5, 2020
File No. 333-236568
Ladies and Gentlemen:
On behalf of our client, Inari Medical, Inc., a Delaware corporation (the “Company”), and pursuant to the applicable provisions of the Securities Act of 1933, as amended (the “Securities Act”), and the rules promulgated thereunder, please find enclosed a complete copy of Amendment No. 2 (“Amendment No. 2”) to the above-captioned Registration Statement on Form S-1 (the “Registration Statement”), which was filed with the Securities and Exchange Commission (the “Commission”) on the date hereof.
Amendment No. 2 reflects certain revisions to the Registration Statement on Form S-1 filed with the Commission on May 5, 2020 (the “Prior Filing”), in response to the comment letter from the staff of the Commission (the “Staff”) to William Hoffman, the Company’s Chief Executive Officer, dated May 12, 2020. The responses provided herein are based on information provided to Latham & Watkins LLP by the Company. For your convenience we are also providing by overnight delivery a courtesy package that includes copies of Amendment No. 2, marked to show changes against the Prior Filing, as well as copy of this letter.
The numbered paragraphs in italics below set forth the Staff’s comment together with the Company’s response thereto. Unless otherwise indicated, capitalized terms used herein have the meanings assigned to them in the Registration Statement.
May 18, 2020
Page 2
Amendment No. 1 to Form S-1 filed on May 5, 2020
Condensed Statements of Operations, page F-32
1. Please revise the filing to present pro forma basic and diluted earnings per share for your latest interim period, March 31, 2020, similar to the presentation included on page F-4 for your fiscal year-end.
Response:
The Company acknowledges the Staff’s comment and, in response to the Staff’s comment, the Company has revised the disclosure on page F-32 of Amendment No. 2.
* * *
May 18, 2020
Page 3
We hope that the foregoing has been responsive to the Staff’s comments and look forward to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact me by telephone at (714) 755-8181 with any questions or further comments you may have regarding this submission or if you wish to discuss the above.
Sincerely,
/s/ B. Shayne Kennedy
Show Raw Text
CORRESP 1 filename1.htm SEC Response Letter 650 Town Center Drive, 20th Floor Costa Mesa, California 92626-1925 Tel: +1.714.540.1235 Fax: +1.714.755.8290 www.lw.com FIRM / AFFILIATE OFFICES May 18, 2020 Beijing Boston Brussels Century City Chicago Dubai Düsseldorf Frankfurt Hamburg Hong Kong Houston London Los Angeles Madrid Milan Moscow Munich New York Orange County Paris Riyadh San Diego San Francisco Seoul Shanghai Silicon Valley Singapore Tokyo Washington, D.C. VIA EDGAR AND OVERNIGHT DELIVERY United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Chris Edwards; Irene Paik; Jeanne Bennett; Kevin Kuhar Re: Inari Medical, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed May 5, 2020 File No. 333-236568 Ladies and Gentlemen: On behalf of our client, Inari Medical, Inc., a Delaware corporation (the “Company”), and pursuant to the applicable provisions of the Securities Act of 1933, as amended (the “Securities Act”), and the rules promulgated thereunder, please find enclosed a complete copy of Amendment No. 2 (“Amendment No. 2”) to the above-captioned Registration Statement on Form S-1 (the “Registration Statement”), which was filed with the Securities and Exchange Commission (the “Commission”) on the date hereof. Amendment No. 2 reflects certain revisions to the Registration Statement on Form S-1 filed with the Commission on May 5, 2020 (the “Prior Filing”), in response to the comment letter from the staff of the Commission (the “Staff”) to William Hoffman, the Company’s Chief Executive Officer, dated May 12, 2020. The responses provided herein are based on information provided to Latham & Watkins LLP by the Company. For your convenience we are also providing by overnight delivery a courtesy package that includes copies of Amendment No. 2, marked to show changes against the Prior Filing, as well as copy of this letter. The numbered paragraphs in italics below set forth the Staff’s comment together with the Company’s response thereto. Unless otherwise indicated, capitalized terms used herein have the meanings assigned to them in the Registration Statement. May 18, 2020 Page 2 Amendment No. 1 to Form S-1 filed on May 5, 2020 Condensed Statements of Operations, page F-32 1. Please revise the filing to present pro forma basic and diluted earnings per share for your latest interim period, March 31, 2020, similar to the presentation included on page F-4 for your fiscal year-end. Response: The Company acknowledges the Staff’s comment and, in response to the Staff’s comment, the Company has revised the disclosure on page F-32 of Amendment No. 2. * * * May 18, 2020 Page 3 We hope that the foregoing has been responsive to the Staff’s comments and look forward to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact me by telephone at (714) 755-8181 with any questions or further comments you may have regarding this submission or if you wish to discuss the above. Sincerely, /s/ B. Shayne Kennedy B. Shayne Kennedy of LATHAM & WATKINS LLP cc: William Hoffman, Inari Medical, Inc. Mitch Hill, Inari Medical, Inc. B. Shayne Kennedy, Latham & Watkins LLP J. Ross McAloon, Latham & Watkins LLP Ilir Mujalovic, Shearman & Sterling LLP